James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Biogen Inc (BIIB) Stock Is Too Much of a Coin Toss

Handicapping Biogen stock (BIIB) for the foreseeable future is too much guesswork, but if the wind blows the right way, look out above.

Why Abercrombie & Fitch Co. (ANF), Hershey Co (HSY) and Newmont Mining Corp (NEM) Are 3 of Today’s Worst Stocks

Abercrombie & Fitch (ANF), Hershey (HSY) and Newmont Mining (NEM) were doomed from the start of Tuesday's trading.

How Twitter Inc (TWTR) Is Stealing YouTube’s Lunch

Twitter stock won't soar on the news, but ad revenue sharing is a sign that Jack Dorsey finally recognizes a major problem with TWTR.

There’s More to Johnson & Johnson (JNJ) Than Meets the Eye

Johnson & Johnson (JNJ) has an impressive pipeline most investors don't fully appreciate. This isn't your father's stock.

Why Gilead Sciences, Inc. (GILD), Valeant Pharmaceuticals Intl Inc (VRX) and Core-Mark Holding Company, Inc. (CORE) Are 3 of Today’s Worst Stocks

Gilead (GILD), Valeant (VRX) and Core-Mark (CORE) were each suspiciously left out of Monday's rally effort.